S Rx Health Solutions Canada Inc
Total Consideration
$6.9M
Purchase-Price Allocation
Assets Acquired
$17.0M
Liabilities Assumed
$6.0M
SRx HEALTH SOLUTIONS, INC. — Key Metrics
3 years of history · ending 2025-09-30 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
M-Score (Beneish; >-1.78 flags risk)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-2
Book Value Per Share
$0
Free Cash Flow Per Share
$-0
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-0
Return on Equity
142.3%
Return on Assets
-371.9%
Return on Invested Capital
28.5%
Debt to Equity
-0.04
Current Ratio
2.29
Quick Ratio
1.71
Asset Turnover
0.54
Days Sales Outstanding
220.37
Days Payables Outstanding
156.48
Days Inventory On Hand
151.45
Cash Conversion Cycle
215.35
R&D / Revenue
0.3%
SBC / Revenue
49.1%
Capex / Revenue
0.1%
Working Capital
$5M
Net Current Asset Value
$131K
Invested Capital
$407K
OCF / Net Income
0.18
FCF / Net Income
0.18
Accruals Ratio (Sloan)
-438.7%
Net Debt
$-1M
Net Debt / EBITDA
0.12
Interest Coverage
-18.16
Cash Coverage
-12.97
Capex Coverage
-106.27
Tangible Common Equity
$407K
TCE / Total Assets
4.8%
Goodwill / Total Assets
2.6%
NOPAT
$-9M
Cash ROIC
25.7%
WC / Revenue
70.1%
Capex / D&A
0.32
Reinvestment Rate
0.3%
Total Payout Ratio
-0.3%
Asset Growth vs Revenue Growth
34.5%
Revenue 5Y CAGR
-32.3%
Book Value 5Y CAGR
-62.9%
Stock Price (FY-end)
$0
Market Cap
$7M
P/E Ratio
—
P/S Ratio
1.02
P/B Ratio
16.44
P/TB Ratio
16.44
P/OCF Ratio
—
P/FCF Ratio
—
Enterprise Value
$5M
EV / EBITDA
15.97
EV / Sales
0.82
EV / FCF
—
FCF Yield
-121.7%
Shareholder Yield
-45.9%
Buyback Yield
2.0%
R&D Yield
3.6%
Capex Yield
1.5%
Graham Number
—
Shares Variation (YoY)
1206.5%
Beta (5Y)
0.86
Cost of Equity
8.8%
Cost of Debt (after tax)
15.3%
WACC
11.7%
ROIC - WACC Spread
-0.4%
52W High
$2
52W Low
$0
Trailing Return 1Y
-79.8%
Trailing Return 5Y
-99.6%
F-Score (Piotroski)
2.00
M-Score (Beneish)
-21.16
Z-Score (Altman)
-6.37
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Stock Price on Earnings Dates
SRx HEALTH SOLUTIONS, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2021 | FY2022 | FY2023 | FY2024 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | -19.00% | 0.40% | 1.30% | — | -1.77% | — |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | — | — | — | — | — | — |
| Valuation Allowance Change | 69.20% | -13.70% | -22.10% | — | 1.53% | 25.00% |
| Effective Tax Rate | 1.10% | 0.10% | 0.00% | — | -6.10% | -0.10% |
Cash vs Accrual
| Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $37.0K | −$18.0K | $2.0K | — | $9.0K | — |
| Income Taxes Paid (Cash) | $8.0K | $12.0K | — | — | — | — |
SRx HEALTH SOLUTIONS, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Better Choice
Total Consideration
$4.1M
Pro-Forma Combined Entity
Revenue
$23.3M
Net Income
−$12.6M